(Q34785845)

4 August 2017

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy (English)

1 reference

4 August 2017

phase I clinical trial

0 references

author name string

L J Hoffer

1

1 reference

4 August 2017

M Levine

2

1 reference

4 August 2017

S Assouline

3

1 reference

4 August 2017

D Melnychuk

4

1 reference

4 August 2017

S J Padayatty

5

1 reference

4 August 2017

K Rosadiuk

6

1 reference

4 August 2017

C Rousseau

7

1 reference

4 August 2017

L Robitaille

8

1 reference

4 August 2017

W H Miller

9

1 reference

4 August 2017

9 June 2008

1 reference

4 August 2017

1 reference

4 August 2017

19

1 reference

4 August 2017

11

1 reference

4 August 2017

1969-1974

1 reference

Vitamin C in alternative cancer treatment: historical background

4 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Vitamins C and K3 sensitize human urothelial tumors to gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Vitamin C enhances chemosensitization of esophageal cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Inhibition of the development of metastases by dietary vitamin C:K3 combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Mitomycin C and menadione for the treatment of lung cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Orthomolecular oncology review: ascorbic acid and cancer 25 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

The use of antioxidant therapies during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

Tumor-targeted induction of oxystress for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN377

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN377

1 reference

4 August 2017

1 reference